A Phase 1 interventional study of Placebo and RO7204239 in Type 2 Diabetes Mellitus, Obesity and Overweight, sponsored by Hoffmann-La Roche. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche — 7 open to participants now, 8 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Hoffmann-La Roche.
Among the 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche, this one is the 61st largest by planned enrollment, is one of 3 that started in 2025, is one of 19 in phase 1, and was the 68th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →7 of the 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States, Puerto Rico
Ages 18+
Hoffmann-La Roche · Sites in United States
Ages 18+
Hoffmann-La Roche · Sites in China
Ages 18+
Hoffmann-La Roche · Sites in United States, Argentina, Australia and 19 more countries
Ages 18+
Hoffmann-La Roche · Sites in United States, Hungary, Poland and 1 more country
Ages 18+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 196 across the 73 interventional studies. Of the 63 that completed or were terminated, 3 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 73 studies in Diabetes Mellitus, Type 2 by Hoffmann-La Roche, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess the effect of RO7204239 on insulin sensitivity versus placebo in participants with T2DM and obesity or overweight.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive RO7204239 matching placebo, every 4 weeks (Q4W), as a subcutaneous (SC) injection for 24 weeks.
Drug: Placebo
Participants will receive RO7204239, Q4W, as a SC injection for 24 weeks.
Drug: RO7204239
RO7204239 matching placebo will be administered as per the schedule specified in the treatment arm.
RO7204239 will be administered as per the schedule specified in the treatment arm.
Also known as: GYM329
Change From Baseline in M-value in a Hyperinsulinemic Euglycemic Glucose Clamp (HEC) at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 12 and 24
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Glucose Metabolism Assessed Using Fasting Glucose Test at Weeks 12 and 24
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Glucose Metabolism Assessed Using Insulin Test at Weeks 12 and 24
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Glucose Metabolism Assessed Using C-peptide Test at Weeks 12 and 24
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Blood Lipid Profiles at Weeks 12 and 24
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Body Weight at Weeks 12 and 24
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Waist Circumference at Weeks 12 and 24
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Waist to Height Ratio at Weeks 12 and 24
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Total Lean Tissue Volume and Total Adipose Tissue Volume From Abdominal Magnetic Resonance Imaging (MRI) at Weeks 12 and 24
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Muscle Volume From Thigh Muscle MRI at Weeks 12 and 24
Time frame: Baseline, Week 12, Week 24
Change From Baseline in Muscle Fat Infiltration From Thigh Muscle MRI at Weeks 12 and 24
Time frame: Baseline, Week 12, Week 24
Number of Participants With Adverse Events (AEs)
Time frame: Up to Week 48
Number of Participants With Local and Systemic Injection Reactions
Time frame: Up to Week 48
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Sep 2026, 11 months.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 11 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emugrobart